The Index
400 dossiers · 1 need attention
A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.
| The credible enzymatic-DNA-synthesis survivor — a real fidelity moat (1,005-base record, 50 kb clonal, ~99.9% stepwise yield) now distributed through Danaher/IDT — but it is a sub-$25M-revenue tools shop selling a faster picks-and-shovels commodity into a brutal synbio funding winter; WATCHING as a private until an IPO path or an IDT buyout crystallizes the value. | — | 8 | |
| The only AI-bio company building a proprietary, legally-clean training dataset 100x deeper than UniProt — own the data layer of TechBio and it is a generational compounder; if foundation labs (ESM, AlphaFold) reach "good enough" on public data first, it is a beautifully-sourced commodity. Watch for an EDEN-derived therapeutic deal with real economics and a priced Series C. | — | 8 | |
| A real lab-in-the-loop antibody-engineering shop with blue-chip pharma validation (AbbVie/Lilly/Merck/Amgen) and now its own clinic-bound ADC — but it is dramatically out-capitalized ($145M vs. $1B+ peers) and is becoming a Lilly satellite; WATCHING as a private, with the IND-into-clinic 2026 prints as the only catalyst that re-rates it. | — | 8 | |
| The single most exciting private name in AI-bio — Chai-2/3 is the first AI antibody platform with a wet-lab-validated, repeatedly-improving hit rate AND signed pharma revenue (Lilly + Pfizer); the bet is whether a portable, lab-light software platform can defend value capture against Isomorphic's deeper engine and the platform-vs-asset value trap. WATCHING for an IPO that is 2-3 years away. | — | 8 | |
| The cleanest pure-SaaS bet in AI protein engineering — Google-pedigreed, wet-lab-backed, already billing 6 of the top-25 pharma — but it has deliberately disarmed itself of the one thing that creates equity value in this field (it owns no molecule, takes no royalty, signs no IP), so it is selling a fast-commoditizing copilot whose best customers (Novo Nordisk) are simultaneously funding the open-source models that erode its moat. | — | 8 |